Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Better healthcare needs the right people and appropriate implementation

This article was originally published in Scrip

Executive Summary

The US health insurance expansion legislation signed into law on 23 March 2010 extends coverage to more Americans and follows the legislation expanding drug coverage for seniors in December 2003 (Medicare Part D). Controversy surrounds the subject of who benefits, who pays, how healthcare is delivered and what proportion of the healthcare dollar is controlled by the government, employers and individuals. The US pharmaceutical industry has supported both the 2003 and 2010 legislations. The industry, in principle, has supported expanded coverage for several years.

You may also be interested in...



CEO CORNER: A new blog feature with Fred Hassan

I have returned from the PhRMA Annual Meeting in San Diego. My recent book was handed out to all registrants of the meeting and I got to hear from many of them. I appreciate feedback. And the takeaways from my book are the same as my own personal playbook.

Lessons in Lifecycle Management: Successors, Flankers and Toppers

Successors, flankers and toppers are product lifecycle management (LCM) categories used by pharma executives, although they may be referred to differently by other companies.

Fred Hassan: Getting traction with lifecycle management

Early in my career, I learned the essential principle of product lifecycle management (LCM): "Do LCM because you create value for the patient or the customer – not just because you want to get more profit out of each molecule."

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel